Published in

Elsevier, The Lancet Diabetes and Endocrinology, 1(10), p. 35-45, 2022

DOI: 10.1016/s2213-8587(21)00292-8

Links

Tools

Export citation

Search in Google Scholar

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

Journal article published in 2022 by Subodh Verma, Nitish K. Dhingra, Javed Butler, Stefan D. Anker, Joao Pedro Ferreira, Gerasimos Filippatos, James L. Januzzi, Carolyn S. P. Lam, Naveed Sattar, Barbara Peil, Matias Nordaby, Martina Brueckmann, Stuart J. Pocock, Faiez Zannad, Milton Packer and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO